Autoimmunity occurs when the body can no longer distinguish between self and non-self. The immune system mistakenly attacks and destroys organs and/or tissues leading to chronic and debilitating disease. Examples include Rheumatoid Arthritis, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Psoriasis, Systemic Lupus Erythematosus.
Expertise in Autoimmunity
ImmuneCarta applies its expertise and uses immune monitoring and flow cytometry to:
- Assess the efficacy of compounds on targeted cell populations
- Identify predictive biomarkers of efficacy and safety
- Enumerate and phenotypically identify cell subsets (Treg, T, B, NK, DC, monocytes)
- Measure cytokine production by ICS (intracellular cytokine staining)
- Measure cellular proliferation by CFSE (carboxyfluorescein succinimidyl ester)
- Assess the impact of kinase inhibitors on protein phosphorylation (Phospho Flow Cytometry)
Clinical trials for kinase inhibitors to treat autoimmune disorders such as RA (rheumatoid arthritis) were successful in specific patient groups.
Combining phenotypic markers to identify cell subsets with ICS (Intracellular Cytokine Staining) for cytokine production, and Phospho Flow Cytometry for kinase activation, provides a comprehensive assessment of the immune picture in untreated and treated disease samples.
For example, immune monitoring can be used to develop more effective and safer kinase inhibitors for the Btk, Syk, and JAK/STAT pathways.
Potential immune monitoring targets for kinase inhibitor therapeutics